Showa University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (1928)

Organization Overview

First Clinical Trial
2003
NCT00190580
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Divison of Nephrology, Department of Medicine, Showa University School of Medicine | Showa University School of Medicine

Active Ingredients

Drugs in Phase 4 Trials (2)

pyridoxine (1 trial)

valsartan (diovan) (1 trial)

Drugs in Phase 3 Trials (4)

calcium carbonate (1 trial)

darbepoetin alfa (aranesp) (1 trial)

lanthanum (1 trial)

pioglitazone (actos) (1 trial)

Drugs in Phase 2 Trials (4)

chitosan (1 trial)

s-488410 (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

Drugs in Other Trials (1)

sertraline (zoloft) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Hyperphosphatemia (Phase 3)

Hypertension (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 3)

Lung Neoplasms (Phase 2)

Nausea (Phase 4)

Pre-Eclampsia (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 11